ImmunitoAI is a biotech platform that employs artificial intelligence to optimize the antibody discovery process for therapeutic applications. This technology significantly reduces the time and costs associated with developing effective treatments by enhancing the identification and refinement of antibodies.
Funding
Funding not disclosed
GFounders
Product
Problem
Traditional antibody discovery processes for therapeutic applications are time-consuming and costly, often involving extensive screening and refinement to identify effective candidates. The reliance on biological sources and exploratory methods can limit efficiency and hinder the development of antibodies with pre-defined drug properties.
Solution
ImmunitoAI is a TechBio company that leverages an AI-driven platform to design novel antibody therapeutics with pre-defined drug characteristics. Their structure-first AI platform uses neural networks trained on shape complementarity to enable precise, target-specific antibody design. This in silico approach eliminates the need for biological sources, allowing for intentional de novo antibody design and expanding the accessible antibody space. The platform computationally screens for ideal drug characteristics early in the process, minimizing the exploratory phase and optimizing for affinity, specificity, and developability.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions seeking to accelerate and improve the efficiency of antibody discovery for therapeutic applications.
Features
- In silico antibody design without reliance on biological sources
- Structure-first AI platform using neural networks trained on shape complementarity
- Computational screening for pre-defined drug properties early in the design process
- Target-specific design for optimized affinity and specificity
- Ability to design antibodies for previously undruggable targets
- In-house biological methods for validating AI-generated antibody therapeutics